Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients.

Armen V Oganesyan Ruslan Menzulin Yury A Surovoy Andrei Nikiforchin Kirill Zykov

Published in: Critical care research and practice (2021)

A 3-day dexamethasone course is not associated with lower 28-day mortality in critically ill COVID-19 patients, either in the entire ICU cohort or in the IMV. Dexamethasone may significantly reduce the 28-day mortality in IMV patients <65 years, but not in the older IMV subgroup. Dexamethasone administration in patients ≥65 years is associated with a significantly higher rate of adverse events than that in younger patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
low dose
peritoneal dialysis
high dose
sars cov
clinical trial
randomized controlled trial
risk factors
cardiovascular events
middle aged
acute respiratory distress syndrome
study protocol
phase iii